Clinical Trials Directory

LIPS-A: Lung Injury Prevention Study With Aspirin

This is a multi-center, phase, phase II double-blind, placebo-controled, randomized trial of aspirin for the prevention of acute lung injury in patients identified as at risk for acute lung injury.

Stanford is now accepting new patients for this trial. Please contact Rosemary Vojnik at 650-723-7409 for more information.



  • drug : Lactose powder
  • drug : Aspirin

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Adult patients (age > 18) admitted to the hospital through the emergency department (ED) - At high risk of developing ALI (Lung Injury Prediction Score-LIPS greater than or equal to 4)

External Links

Contact information

Primary Contact:

Rosemary Vojnik 650-723-7409

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: